Evenemang

DuoCort presents phase II/III data at ENDO in Washington DC June 12th

2009-06-04 11:15
Duocort_logo

Tid: 2009-06-10 - 2009-06-13
Plats: Washington DC, USA

ENDO 09, The Endocrine Society's Annual Meeting, offers an unparalleled opportunity to learn about the latest advances in endocrine research and clinical care, while networking and collaborating with more than 7,500 colleagues from around the world. Wednesday, June 10 through Saturday, June 13, 2009

Kategorisering

Ämnen:
Forskning,
Medicin,
Medicin, läkemedel,
Medicinsk forskning
Tags:
fas ii/iii data,
endo,
duocort,
endo 09
Typ av evenemang:
Konferenser och kongresser

Relaterade pressmeddelanden

Lyckad svensk fas II/III studie för ny behandling av Addisons sjukdom

2009-06-15 09:00 Helsingborg / Washington DC 12 juni 2009- Svenska företaget DuoCort har fått lovande data från sin fas II/III studie för den ovanliga och livshotande Addisons sjukdom. DuoCorts nya mer fysiologiska behandlingsform med hydrokortison givet en gång om dagen visar förbättrade riskfaktorer för hjärt-kärlsjukdom jämfört med dagens standardbehandling med hydrokortison som ofta ges tre gånger om dagen.

Successful phase II/III trial of new therapy for Addison´s disease

2009-06-12 06:00 Helsingborg/ Washington DC June 12th 2009- DuoCort gained promising data from its Phase II/III study for the rare and life threatening disease adrenal insufficiency. DuoCort’s new form of physiological treatment with once daily dosing show improved cardiovascular measures compared to standard hydrocortisone given thrice daily. The company presents the data at the ENDO congress in Washington DC.

Se fler (2)

Relaterade evenemang

DuoCort presents new data at The Endocrine Society´s annual meeting in the US

DuoCort presents new data at The Endocrine Society´s annual meeting in the US

2010-04-15 16:33 DuoCort has three accepted abstracts with new data at the annual congress, ENDO, arranged by the American Endocrine Society. The data that will be presented are: - Quality of life data from the ph II/III trial - Dose individualisation - A world wide patient survey with over 1200 respondents

Tid: 2010-06-19 - 2010-06-22
Plats: San Diego, California, USA

Se fler (1)

Kommentarer (0)

Lägg till kommentar